Immunohistochemistry (IHC): Increase the Success of Biomarker Integration in Clinical Development

“With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, you can increase the success of biomarker integration in clinical development.”

– Amanda Finan, PhD, Head IHC/Histology R&D and Clinical Validations at Cerba Research

Pediatric Phase I/II Clinical Trial on Mucopolysaccharidosis type III (MPSIIIA)

Lab support for a global pediatric trial for the rare genetic neurodegenerative disorder, Mucopolysaccharidosis type III. Cerba Research provided safety testing, sample management, and specialized testing in our histology lab. Read the case study to discover more details.

Pediatric Phase I/II/III Study in X-Linked Myotubular Myopathy (XLMTM)

Lab support for a global pediatric trial for the rare neuromuscular disease, Myotubular Myopathy. Cerba Research provides safety testing, PBMC isolation, biomarkers, and sample management for the clinical trial. Read more on the challenges and solutions in the case study.